FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Horsman

Research Profile

Living Beings

Disorders

Physiology

Chemicals & Drugs

Procedures

Phenomena

Partial Pressure

Co-author Network

Publications

TOP 3
Martin Busk; F P D'Andrea; K V Hansen; Steen Jakobsen; J F Kallehauge; Leif Spange Mortensen; Marianne Nordsmark; Jens Overgaard; Torben Steiniche; J Theil; Michael R Horsman
PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.
Michael R Horsman; Lise Saksø Mortensen; Martin Busk; Jørgen B Petersen; Jens Overgaard
Imaging hypoxia to improve radiotherapy outcome.
Anja B Bohn; Elena V Bouzinova; Robert A Fenton; Jørgen Frøkiaer; Michael R Horsman; Vladimir V Matchkov; Rikke Nørregaard; Lene Stødkilde; Lotte B Bertelsen; Yan Wang; Hans Stødkilde-Jørgensen
Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Horsman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Martin Busk; F P D'Andrea; K V Hansen; Steen Jakobsen; J F Kallehauge; Leif Spange Mortensen; Marianne Nordsmark; Jens Overgaard; Torben Steiniche; J Theil; Michael R Horsman
PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.
European journal of nuclear medicine and molecular imaging 2013;40(2):186-97.
2012: Michael R Horsman; Lise Saksø Mortensen; Martin Busk; Jørgen B Petersen; Jens Overgaard
Imaging hypoxia to improve radiotherapy outcome.
Nature reviews. Clinical oncology 2012;9(12):674-87.
2012: Anja B Bohn; Elena V Bouzinova; Robert A Fenton; Jørgen Frøkiaer; Michael R Horsman; Vladimir V Matchkov; Rikke Nørregaard; Lene Stødkilde; Lotte B Bertelsen; Yan Wang; Hans Stødkilde-Jørgensen
Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output.
American journal of physiology. Regulatory, integrative and comparative physiology 2012;303(2):R186-98.
2012: Filippo P D'Andrea; Michael R Horsman; Moustapha Kassem; Jorge S Burns; Akmal Safwat; Jens Overgaard
Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells.
International journal of radiation biology 2012;88(6):457-65.
2012: Filippo P D'Andrea; Michael R Horsman; Moustapha Kassem; Jens Overgaard; Akmal Safwat
Tumourigenicity and radiation resistance of mesenchymal stem cells.
Acta oncologica (Stockholm, Sweden) 2012;51(5):669-79.
2012: Thomas Wittenborn; Michael R Horsman; Jørgen Kjems; Esben K U Larsen; Niels Chr Nielsen; Thomas Nielsen; Jens V Nygaard; Louise M Rydtoft; Troels Thim; Thomas Vorup-Jensen; Erling Falk
Ultrahigh-field DCE-MRI of angiogenesis in a novel angiogenesis mouse model.
Journal of magnetic resonance imaging : JMRI 2012;35(3):703-10.
2011: Lotte B Bertelsen; G Kenneth Lloyd; Thomas Nielsen; Yuan Yuan Shen; Dietmar W Siemann; Hans Stødkilde-Jørgensen; Michael R Horsman
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.
International journal of radiation biology 2011;87(11):1126-34.
2011: Lise Saksø Mortensen; Marianne Nordsmark; Jens Overgaard; Jørn Theil; Martin Busk; Steen Jakobsen; Michael R Horsman
Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011;99(3):418-23.
2011: Filippo P D'Andrea; Laurant Gautier; Moustapha Kassem; Jens Overgaard; Akmal Safwat; Michael R Horsman
Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011;99(3):373-8.
2011: Martin Busk; Michael R Horsman; Steen Jakobsen; Wolfgang Mueller-Klieser; Torben Steiniche; Stefan Walenta; Jens Overgaard
Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011;99(3):404-11.
2011: Morten Busk; Kasper Toustrup; Boe Sandahl Sørensen; Jan Alsner; Michael R Horsman; Steen Jakobsen; Jens Overgaard
In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors.
BMC cancer 2011;11():63.
2011: Martin Busk; Anja Bille Bohn; Marianne Skals; Tobias Wang; Michael R Horsman
Combretastatin-induced hypertension and the consequences for its combination with other therapies.
Vascular pharmacology 2011;54(1-2):13-7.
2010: Birgitte Vrou Offersen; Marianne M Knap; Michael R Horsman; Jan Verheijen; roeland hanemaaijer; Jens Overgaard
Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival.
Acta oncologica (Stockholm, Sweden) 2010;49(8):1283-7.
2010: Morten Busk; Ole Lajord Munk; Steen Jakobsen; Tobias Wang; Marianne Skals; Torben Steiniche; Michael R Horsman; Jens Overgaard
Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET.
Acta oncologica (Stockholm, Sweden) 2010;49(7):922-33.
2010: Thomas Nielsen; Rumi Murata; Ross J Maxwell; Hans Stødkilde-Jørgensen; Leif Ostergaard; Carsten D Ley; Paul E.G. Kristjansen; Michael R Horsman
Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.
Acta oncologica (Stockholm, Sweden) 2010;49(7):906-13.
2010: Boe Sandahl Sørensen; Kasper Toustrup; Michael R Horsman; Jens Overgaard; Jan Alsner
Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro.
Acta oncologica (Stockholm, Sweden) 2010;49(7):895-905.
2010: Michael R Horsman; A B Bohn; Martin Busk
Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Experimental oncology 2010;32(3):143-8.
2010: Benedikte Hasselbalch; Jesper Grau Eriksen; Helle Broholm; Ib Jarle Christensen; Kirsten Grunnet; Michael R Horsman; Hans Skovgaard Poulsen; Marie-Thérése Stockhausen; Ulrik Lassen
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2010;118(8):585-94.
2010: Lise Falborg; Lasse N Waehrens; Jan Alsner; Henrik Bluhme; Jørgen Frøkiaer; christian heegaard; Michael R Horsman; Jan T Rasmussen; Michael Rehling
Biodistribution of 99mTc-HYNIC-lactadherin in mice--a potential tracer for visualizing apoptosis in vivo.
Scandinavian journal of clinical and laboratory investigation 2010;70(3):209-16.
2010: Steffen L Hokland; Thomas Nielsen; Morten Busk; Michael R Horsman
Imaging tumour physiology and vasculature to predict and assess response to heat.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2010;26(3):264-72.
2009: Morten Busk; Michael R Horsman; Steen Jakobsen; Kim V Hansen; Johan Bussink; Albert J van der Kogel; Jens Overgaard
Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;92(3):429-36.
2009: Brita Sørensen; Michael R Horsman; Henrik Vorum; Bent Honoré; Jens Overgaard; Jan Alsner
Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;92(3):443-9.
2009: Dietmar W Siemann; Michael R Horsman
Vascular targeted therapies in oncology.
Cell and tissue research 2009;335(1):241-8.
2008: Morten Busk; Michael R Horsman; Paul E.G. Kristjansen; Albert J van der Kogel; Johan Bussink; Jens Overgaard
Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia.
International journal of cancer. Journal international du cancer 2008;122(12):2726-34.
2008: Rumi Murata; Michihiko Tsujitani; Michael R Horsman
Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2008;87(3):331-8.
2008: Morten Busk; Michael R Horsman; Steen Jakobsen; Susanne Keiding; Albert J van der Kogel; Johan Bussink; Jens Overgaard
Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy.
International journal of radiation oncology, biology, physics 2008;70(4):1202-12.
2008: Thomas Nielsen; Rumi Murata; Ross J Maxwell; Hans Stødkilde-Jørgensen; Leif Ostergaard; Michael R Horsman
Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
International journal of radiation oncology, biology, physics 2008;70(3):859-66.
2008: Michael R Horsman
Angiogenesis and vascular targeting: relevance for hyperthermia.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2008;24(1):57-65.
2008: Gang Chen; Michael R Horsman; Michael Pedersen; Qi Pang; Hans Stødkilde-Jørgensen
The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Acta oncologica (Stockholm, Sweden) 2008;47(6):1071-6.
2008: Thomas Nielsen; Kim Mouridsen; Ross J Maxwell; Hans Stødkilde-Jørgensen; Leif Østergaard; Michael R Horsman
Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
Acta oncologica (Stockholm, Sweden) 2008;47(7):1265-70.
2008: Morten Busk; Michael R Horsman; Jens Overgaard
Resolution in PET hypoxia imaging: voxel size matters.
Acta oncologica (Stockholm, Sweden) 2008;47(7):1201-10.
2008: Slavka Lukacova; Boe Sandahl Sørensen; Jan Alsner; Jens Overgaard; Michael R Horsman
The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models.
Acta oncologica (Stockholm, Sweden) 2008;47(5):941-7.
2007: S L Hokland; Michael R Horsman
The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2007;23(7):599-606.
2007: Michael R Horsman; Jens Overgaard
Hyperthermia: a potent enhancer of radiotherapy.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2007;19(6):418-26.
2007: Brita Sørensen; Jan Alsner; Jens Overgaard; Michael R Horsman
Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2007;83(3):362-6.
2007: Marianne Nordsmark; Jesper Grau Eriksen; Val Gebski; Jan Alsner; Michael R Horsman; Jens Overgaard
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2007;83(3):389-97.
2006: Michael R Horsman; Dietmar W Siemann
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Cancer research 2006;66(24):11520-39.
2006: Jesper Grau Eriksen; Michael R Horsman
Tumour hypoxia - a characteristic feature with a complex molecular background.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2006;81(2):119-21.
2006: Slavka Lukacova; Jens Overgaard; Jan Alsner; Michael R Horsman
Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2006;80(2):165-71.
2006: David J Chaplin; Michael R Horsman; Dietmar W Siemann
Current development status of small-molecule vascular disrupting agents.
Current opinion in investigational drugs (London, England : 2000) 2006;7(6):522-8.
2006: Michael R Horsman
Tissue physiology and the response to heat.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(3):197-203.
2006: Michael R Horsman; Lothar Bohm; Geoffrey P Margison; Luka Milas; Jean-Francois Rosier; Geza Safrany; Edgar Selzer; Marcel Verheij; Jolyon H Hendry
Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting.
International journal of radiation oncology, biology, physics 2006;64(2):551-61.
2006: Michael R Horsman; Thomas Nielsen; Leif Østergaard; Jens Overgaard
Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response.
Acta oncologica (Stockholm, Sweden) 2006;45(7):876-80.
2006: Tomas Breidahl; Flemming U Nielsen; Hans Stødkilde-Jørgensen; Ross J Maxwell; Michael R Horsman
The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Acta oncologica (Stockholm, Sweden) 2006;45(3):306-16.
2005: Slavka Lukacova; Azza A Khalil; Jens Overgaard; Jan Alsner; Michael R Horsman
Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum.
International journal of radiation biology 2005;81(12):937-44.
2005: Jens Overgaard; Jesper Grau Eriksen; Marianne Nordsmark; Jan Alsner; Michael R Horsman
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
The lancet oncology 2005;6(10):757-64.
2005: Gang Chen; Sune Nørhøj Jespersen; Michael Pedersen; Qi Pang; Michael R Horsman; Hans Stødkilde-Jørgensen
Evaluation of anti-vascular therapy with texture analysis.
Anticancer research 2005;25(5):3399-405.
2005: Brita Sørensen; Jing Hao; Jens Overgaard; Henrik Vorum; Bent Honoré; Jan Alsner; Michael R Horsman
Influence of oxygen concentration and pH on expression of hypoxia induced genes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;76(2):187-93.
2005: Mette Sørensen; Michael R Horsman; Paul Cumming; Ole Lajord Munk; Susanne Keiding
Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.
International journal of radiation oncology, biology, physics 2005;62(3):854-61.
2005: Gang Chen; Sune Nørhøj Jespersen; Michael Pedersen; Qi Pang; Michael R Horsman; Hans Stødkilde-Jørgensen
Intravenous administration of Gd-DTPA prior to DWI does not affect the apparent diffusion constant.
Magnetic resonance imaging 2005;23(5):685-9.
2005: Martin Leach; K M Brindle; Jeffrey L Evelhoch; John R Griffiths; Michael R Horsman; A Jackson; G C Jayson; Ian R Judson; M V Knopp; Ross J Maxwell; D McIntyre; Anwar R Padhani; P Price; R Rathbone; Gordon J S Rustin; P S Tofts; Gillian M Tozer; W Vennart; John C Waterton; S R Williams; Paul Workman
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
British journal of cancer 2005;92(9):1599-610.
2005: Lise Bentzen; Peter Vestergaard-Poulsen; Thomas Nielsen; Jens Overgaard; Atle Bjørnerud; Karen Briley-Saebø; Michael R Horsman; Leif Ostergaard
Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor.
International journal of radiation oncology, biology, physics 2005;61(4):1208-15.
2005: Dietmar W Siemann; Michael C Bibby; Graham G Dark; Adam Dicker; Ferry A L M Eskens; Michael R Horsman; Dieter Marmé; Patricia M LoRusso
Differentiation and definition of vascular-targeted therapies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):416-20.
2004: Dietmar W Siemann; David J Chaplin; Michael R Horsman
Vascular-targeting therapies for treatment of malignant disease.
Cancer 2004;100(12):2491-9.
2004: Rumi Murata; Michael R Horsman
Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2004;20(4):393-404.
2004: Dietmar W Siemann; Michael R Horsman
Targeting the tumor vasculature: a strategy to improve radiation therapy.
Expert review of anticancer therapy 2004;4(2):321-7.
2004: Tove Grönroos; Lise Bentzen; Päivi Marjamäki; Rumi Murata; Michael R Horsman; Susanne Keiding; Olli Eskola; Merja Haaparanta; Heikki Minn; Olof Solin
Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
European journal of nuclear medicine and molecular imaging 2004;31(4):513-20.
2004: Michael R Horsman; Jens Overgaard
Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;70(3):301-9.
2003: Michael R Horsman; Rumi Murata
Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
International journal of radiation oncology, biology, physics 2003;57(4):1047-55.
2002: Birgitte Vrou Offersen; M M Knap; Niels Marcussen; Michael R Horsman; Stephen Hamilton-Dutoit; Jens Overgaard
Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis.
British journal of cancer 2002;87(12):1422-30.
2002: Michael R Horsman; Rumi Murata
Combination of vascular targeting agents with thermal or radiation therapy.
International journal of radiation oncology, biology, physics 2002;54(5):1518-23.
2002: Dietmar W Siemann; Michael R Horsman
Enhancement of radiation therapy by vascular targeting agents.
Current opinion in investigational drugs (London, England : 2000) 2002;3(11):1660-5.
2002: Lise Bentzen; Susanne Keiding; Michael R Horsman; Tove Grönroos; Søren B Hansen; Jens Overgaard
Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing.
Acta oncologica (Stockholm, Sweden) 2002;41(3):304-12.
2001: Rumi Murata; Jens Overgaard; Michael R Horsman
Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.
International journal of radiation oncology, biology, physics 2001;51(4):1018-24.
2001: Rumi Murata; Jens Overgaard; Michael R Horsman
Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2001;17(6):508-19.
2001: Rumi Murata; Dietmar W Siemann; Jens Overgaard; Michael R Horsman
Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Radiation research 2001;156(5 Pt 1):503-9.
2001: Rumi Murata; Dietmar W Siemann; Jens Overgaard; Michael R Horsman
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2001;60(2):155-61.
2001: Flemming U Nielsen; P Daugaard; Lise Bentzen; Hans Stødkilde-Jørgensen; Jens Overgaard; Michael R Horsman; Ross J Maxwell
Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy.
Cancer research 2001;61(13):5318-25.
2001: Marianne Nordsmark; Jan Alsner; J Keller; Ole Steen Nielsen; Olaf Myhre Jensen; Michael R Horsman; Jens Overgaard
Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations.
British journal of cancer 2001;84(8):1070-5.
2001: Rumi Murata; Jens Overgaard; Michael R Horsman
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
International journal of radiation biology 2001;77(2):195-204.
2001: Michael R Horsman; Rumi Murata; Jens Overgaard
Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation.
Acta oncologica (Stockholm, Sweden) 2001;40(4):497-503.
2000: Lise Bentzen; Michael R Horsman; P Daugaard; Ross J Maxwell
Non-invasive tumour blood perfusion measurement by 2H magnetic resonance.
NMR in biomedicine 2000;13(8):429-37.
2000: Dietmar W Siemann; Kenneth H Warrington; Michael R Horsman
Targeting tumor blood vessels: an adjuvant strategy for radiation therapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2000;57(1):5-12.
2000: J Overgaard; Jan Alsner; J Eriksen; Michael R Horsman; C Grau
Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck.
Rays 2000;25(3):313-9.
2000: Lise Bentzen; Susanne Keiding; Michael R Horsman; Lise Falborg; Søren B Hansen; Jens Overgaard
Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose.
Acta oncologica (Stockholm, Sweden) 2000;39(5):629-37.
2000: Michael R Horsman; Rumi Murata; Tomas Breidahl; Flemming U Nielsen; Ross J Maxwell; H Stødkiled-Jørgensen; Jens Overgaard
Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy.
Advances in experimental medicine and biology 2000;476():311-23.
1999: Eva Ehrnrooth; Hans von der Maase; Boe Sandahl Sorensen; JH Poulsen; Michael R Horsman
The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo.
International journal of radiation biology 1999;75(7):885-91.
1999: Flemming U Nielsen; S Topp; Michael R Horsman; Jens Overgaard; Hans Stødkilde-Jørgensen; Ross J Maxwell
Localized in vivo 1H NMR spectroscopy of murine tumours: effect of blood flow reduction.
NMR in biomedicine 1999;12(4):175-83.
1998: Michael R Horsman; Marianne Nordsmark; Jens Overgaard
Techniques to assess the oxygenation of human tumors. State of the art.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1998;174 Suppl 4():2-5.
1998: Michael R Horsman; Eva Ehrnrooth; M Ladekarl; Jens Overgaard
The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
International journal of radiation oncology, biology, physics 1998;42(4):895-8.
1998: Ross J Maxwell; Flemming U Nielsen; Tomas Breidahl; Hans Stødkilde-Jørgensen; Michael R Horsman
Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.
International journal of radiation oncology, biology, physics 1998;42(4):891-4.
1998: Michael R Horsman
Measurement of tumor oxygenation.
International journal of radiation oncology, biology, physics 1998;42(4):701-4.
1998: Dietmar W Siemann; I M Johansen; Michael R Horsman
Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph.
International journal of radiation oncology, biology, physics 1998;40(5):1171-6.
1998: Michael R Horsman; Jan Alsner; Jens Overgaard
The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma.
Acta oncologica (Stockholm, Sweden) 1998;37(5):441-5.
1998: Eric O Aboagye; Ross J Maxwell; Michael R Horsman; AD Lewis; Paul Workman; M Tracy; John R Griffiths
The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.
British journal of cancer 1998;77(1):65-70.
1997: Michael R Horsman; Dietmar W Siemann; D J Chaplin; Jens Overgaard
Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1997;45(2):167-74.
1997: Eric O Aboagye; Ross J Maxwell; AB Kelson; M Tracy; AD Lewis; M A Graham; Michael R Horsman; John R Griffiths; Paul Workman
Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
Cancer research 1997;57(15):3314-8.
1997: Michael R Horsman; Jens Overgaard
Can mild hyperthermia improve tumour oxygenation?
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1997;13(2):141-7.
1997: Marianne Nordsmark; Ross J Maxwell; Michael R Horsman; Søren M Bentzen; Jens Overgaard
The effect of hypoxia and hyperoxia on nucleoside triphosphate/inorganic phosphate, pO2 and radiation response in an experimental tumour model.
British journal of cancer 1997;76(11):1432-9.
1996: Michael R Horsman; L E Sampson; D J Chaplin; Jens Overgaard
The in vivo interaction between flavone acetic acid and hyperthermia.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1996;12(6):779-89.
1996: Marianne Nordsmark; R J Maxwell; P J Wood; I J Stratford; G E Adams; Jens Overgaard; Michael R Horsman
Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.
The British journal of cancer. Supplement 1996;27():S232-5.
1996: Michael R Horsman; D J Chaplin; S A Hill; S Arnold; D Collingridge; M Radacic; P J Wood; Jens Overgaard
Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.
The British journal of cancer. Supplement 1996;27():S168-71.
1996: P J Wood; Michael R Horsman; A A Khalil; F Steinberg; C Streffer; Jens Overgaard; Ian J Stratford; GE Adams
A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.
Acta oncologica (Stockholm, Sweden) 1996;35(8):989-94.
1995: Michael R Horsman; Marianne Nordsmark; Morten Høyer; Jens Overgaard
Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.
British journal of cancer 1995;72(6):1474-8.
1995: E M Lynch; L E Sampson; A A Khalil; Michael R Horsman; D J Chaplin
Cytotoxic effect of tumour necrosis factor -alpha on sarcoma F cells at tumour relevant oxygen tensions.
Acta oncologica (Stockholm, Sweden) 1995;34(3):423-7.
1995: Marianne Nordsmark; C Grau; Michael R Horsman; H S Jörgensen; Jens Overgaard
Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model.
Acta oncologica (Stockholm, Sweden) 1995;34(3):329-34.
1995: Michael R Horsman; C Grau; Jens Overgaard
Reoxygenation in a C3H mouse mammary carcinoma. The importance of chronic rather than acute hypoxia.
Acta oncologica (Stockholm, Sweden) 1995;34(3):325-8.
1995: A A Khalil; Michael R Horsman; Jens Overgaard
The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation.
Acta oncologica (Stockholm, Sweden) 1995;34(3):297-300.
1995: Michael R Horsman
Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review.
Acta oncologica (Stockholm, Sweden) 1995;34(5):571-87.
1995: Michael R Horsman; A A Khalil; D J Chaplin; Jens Overgaard
The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma.
Acta oncologica (Stockholm, Sweden) 1995;34(3):443-6.
1994: Michael R Horsman; K L Christensen; Jens Overgaard
Importance of nicotinamide dose on blood pressure changes in mice and humans.
International journal of radiation oncology, biology, physics 1994;29(3):455-8.
1994: C Grau; Marianne Nordsmark; A A Khalil; Michael R Horsman; Jens Overgaard
Effect of carbon monoxide breathing on hypoxia and radiation response in the SCCVII tumor in vivo.
International journal of radiation oncology, biology, physics 1994;29(3):449-54.
1994: Michael R Horsman; A A Khalil; D W Siemann; C Grau; S A Hill; E M Lynch; D J Chaplin; Jens Overgaard
Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation.
International journal of radiation oncology, biology, physics 1994;29(3):439-42.
1994: Michael R Horsman; D J Chaplin
Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide.
British journal of cancer 1994;69(4):648-54.
1994: C Grau; A A Khalil; Marianne Nordsmark; Michael R Horsman; Jens Overgaard
The relationship between carbon monoxide breathing, tumour oxygenation and local tumour control in the C3H mammary carcinoma in vivo.
British journal of cancer 1994;69(1):50-7.
1994: Michael R Horsman; A A Khalil; Marianne Nordsmark; C Grau; Jens Overgaard
Measurement of pO2 in a murine tumour and its correlation with hypoxic fraction.
Advances in experimental medicine and biology 1994;345():493-500.
1994: Michael R Horsman; Marianne Nordsmark; A Khalil; D J Chaplin; Jens Overgaard
Tumour radiosensitization by nicotinamide: is it the result of an improvement in tumour oxygenation?
Advances in experimental medicine and biology 1994;345():403-9.
1994: Michael R Horsman; Marianne Nordsmark; A A Khalil; S A Hill; D J Chaplin; D W Siemann; Jens Overgaard
Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing.
Acta oncologica (Stockholm, Sweden) 1994;33(4):371-6.
1994: Michael R Horsman; D W Siemann; Marianne Nordsmark; A A Khalil; Jens Overgaard; D J Chaplin
The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment.
Advances in experimental medicine and biology 1994;361():635-42.
1993: Jens Overgaard; M Radacic; D Skaric; V Skaric; Michael R Horsman; Jacob Christian Lindegaard; J Jercic
Use of tetrahydraindazolone dicarboxylic acid (HIDA) to improve the therapeutic effect in vivo of combined cisplatin, heat and radiation treatment.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1993;9(6):821-30.
1993: Michael R Horsman; A A Khalil; Marianne Nordsmark; C Grau; Jens Overgaard
Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1993;28(1):69-71.
1993: Michael R Horsman; Morten Høyer; D J Honess; I F Dennis; Jens Overgaard
Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1993;27(2):131-9.
1993: M Radacic; Jens Overgaard; D Skaric; V Skaric; Michael R Horsman
Reduction of cisplatinum-induced renal toxicity in mice by tetrahydroindazolonecarboxylic acid (HIDA) [corrected].
Acta oncologica (Stockholm, Sweden) 1993;32(1):53-6.
1992: Michael R Horsman; Jens Overgaard
BW12C-induced changes in haemoglobin-oxygen affinity in mice and its influence on the radiation response of a C3H mouse mammary carcinoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1992;25(1):43-8.
1992: Michael R Horsman; K L Christensen; Jens Overgaard
Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure.
International journal of radiation oncology, biology, physics 1992;22(3):455-8.
1992: C Grau; Michael R Horsman; Jens Overgaard
Influence of carboxyhemoglobin level on tumor growth, blood flow, and radiation response in an experimental model.
International journal of radiation oncology, biology, physics 1992;22(3):421-4.
1992: C Grau; Michael R Horsman; Jens Overgaard
Improving the radiation response in a C3H mouse mammary carcinoma by normobaric oxygen or carbogen breathing.
International journal of radiation oncology, biology, physics 1992;22(3):415-9.
1992: Jacob Christian Lindegaard; M Radacic; A A Khalil; Michael R Horsman; Jens Overgaard
Cisplatin and hyperthermia treatment of a C3H mammary carcinoma in vivo. Importance of sequence, interval, drug dose, and temperature.
Acta oncologica (Stockholm, Sweden) 1992;31(3):347-51.
1992: Michael R Horsman; Paul E.G. Kristjansen; M Mizuno; K L Christensen; D J Chaplin; B Quistorff; Jens Overgaard
Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice.
International journal of radiation oncology, biology, physics 1992;22(3):451-4.
1991: Jens Overgaard; C Grau; Jacob Christian Lindegaard; Michael R Horsman
The potential of using hyperthermia to eliminate radioresistant hypoxic cells.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;20 Suppl 1():113-6.
1991: R V Fisker; Michael R Horsman; Jens Overgaard
Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues.
Acta oncologica (Stockholm, Sweden) 1991;30(5):641-7.
1991: Michael R Horsman; D J Chaplin; Jens Overgaard
The use of blood flow modifiers to improve the treatment response of solid tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;20 Suppl 1():47-52.
1990: Michael R Horsman; D J Chaplin; Jens Overgaard
Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells.
Cancer research 1990;50(23):7430-6.
1990: K L Christensen; Michael R Horsman; Jens Overgaard
Invasive blood pressure measurements in restrained but non-anaesthetized mice.
In vivo (Athens, Greece) 1990;4(1):13-6.
1989: Michael R Horsman; P V Hansen; Jens Overgaard
Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status.
International journal of radiation oncology, biology, physics 1989;16(5):1273-6.
1989: Michael R Horsman; K L Christensen; Jens Overgaard
Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1989;5(2):123-36.
1989: Michael R Horsman; J Winther
Vascular effects of photodynamic therapy in an intraocular retinoblastoma-like tumour.
Acta oncologica (Stockholm, Sweden) 1989;28(5):693-7.
1989: Michael R Horsman; Jens Overgaard; K L Christensen; M J Trotter; D J Chaplin
Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy.
Biomedica biochimica acta 1989;48(2-3):S251-4.